NOR-101 — Interim data
by mid-2027
North Immunology's Phase 1a study of NOR-101 is expected to begin in Q1 2027, with interim PK and safety data expected by mid-2027.Source filing
AEMD biotech catalysts & pipeline
AETHLON MEDICAL INC · Data as of 2026-10-25
Upcoming catalysts
NOR-101 — Topline data
2028
Phase 1a study of NOR-101 is expected to begin in the first quarter of 2027, with interim pharmacokinetic and safety data expected by mid-2027 and Phase 1b and Phase 2b topline data expected in 2028Source filing